Page 3 - தேர்ந்தெடுக்கப்பட்ட தடுப்பான் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from தேர்ந்தெடுக்கப்பட்ட தடுப்பான். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In தேர்ந்தெடுக்கப்பட்ட தடுப்பான் Today - Breaking & Trending Today

Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021

/PRNewswire/ Karyopharm Therapeutics Inc. (NASDAQ:KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that. ....

Karyopharm Therapeutics Inc , Karyopharm Selective Inhibitor Of Nuclear Export , European Commission , Karyopharm Therapeutics , Selective Inhibitor , Nuclear Export , ஐரோப்பிய தரகு , தேர்ந்தெடுக்கப்பட்ட தடுப்பான் , அணு ஏற்றுமதி ,

Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021

Karyopharm to Report First Quarter 2021 Financial Results on May 3, 2021
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Karyopharm Therapeutics Inc , Karyopharm Selective Inhibitor Of Nuclear Export , European Commission , Karyopharm Therapeutics , Selective Inhibitor , Nuclear Export , ஐரோப்பிய தரகு , தேர்ந்தெடுக்கப்பட்ட தடுப்பான் , அணு ஏற்றுமதி ,

Karyopharm Announces European Medicines Agency's Validation of its Type II Variation Marketing Authorization Application for NEXPOVIO®

Published: Apr 26, 2021

NEWTON, Mass., April 26, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the European Medicines Agency (EMA) has validated the Company s Type II Variation Marketing Authorization Application (MAA), which seeks to expand the currently authorized indication for NEXPOVIO® in the European Union to include, in combination with Velcade® (bortezomib) and low-dose dexamethasone, the treatment of adult patients with multiple myeloma who have received at least one prior therapy. Validation of the application confirms the submission is complete to begin the EMA s review process. The MAA is supported by the positive results from the pivotal Phase 3 BOSTON study, which evaluated once-weekly selinexor in combination with once-weekly Velcade® and low-dose dexamethasone (SVd) compared to standard twice-weekly Velcade® plus low-dose dexam ....

United States , Sharon Shacham , Selective Inhibitor Of Nuclear Export , Karyopharm Therapeutics Inc , World Health Organization , European Commission , Drug Administration , Takeda Pharmaceutical Company , Company Type Ii Variation Marketing Authorization Application , Prnewswire Karyopharm Therapeutics Inc , Exchange Commission , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , European Medicines Agency , Committee For Medicinal Products Human Use , Marketing Authorization Application , Chief Scientific Officer , Medicinal Products , Human Use , Multiple Myeloma , Selective Inhibitor , Nuclear Export , Product Characteristics , Private Securities Litigation Reform Act , Annual Report , Karyopharm Therapeutics ,

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
News provided by
Share this article
Share this article
NEWTON, Mass., March 1, 2021 /PRNewswire/ Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm s Board of Directors granted stock options to purchase an aggregate of 93,600 shares of Karyopharm s common stock to 11 newly-hired employees, with a grant date of February 26, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4).
Each of the stock options has an exercise price of $13.82 per share, the closing price of Karyopharm s common stock on February 26, 2021. Each stock option vests over four years, with 25% of the total number of shares underlying the stock option vest ....

Karyopharm Therapeutics Inc , Karyopharm Selective Inhibitor Of Nuclear Export , Compensation Committee Of Karyopharm Board Directors , European Medicines Agency , Karyopharm Therapeutics , Compensation Committee , Nasdaq Listing Rule , Selective Inhibitor , Nuclear Export , Marketing Authorization Application , European Medicines , இழப்பீடு குழு , நாஸ்டாக் பட்டியல் ஆட்சி , தேர்ந்தெடுக்கப்பட்ட தடுப்பான் , அணு ஏற்றுமதி , சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம் , ஐரோப்பிய மருந்துகள் ,

Karyopharm Announces Upcoming Virtual Investor Conference Participation

Karyopharm Announces Upcoming Virtual Investor Conference Participation
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

Michael Kauffman , Karyopharm Therapeutics Inc , Karyopharm Selective Inhibitor Of Nuclear Export , European Medicines Agency , Karyopharm Therapeutics , Chief Executive Officer , Annual Global Healthcare Conference , Barclays Global Healthcare , Annual Global Healthcare , Selective Inhibitor , Nuclear Export , Marketing Authorization Application , European Medicines , மைக்கேல் காஃப்மந் , தலைமை நிர்வாகி அதிகாரி , ஆண்டு உலகளாவிய சுகாதாரம் மாநாடு , பார்க்லேஸ் உலகளாவிய சுகாதாரம் , ஆண்டு உலகளாவிய சுகாதாரம் , தேர்ந்தெடுக்கப்பட்ட தடுப்பான் , அணு ஏற்றுமதி , சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம் , ஐரோப்பிய மருந்துகள் ,